OncoMatch/Clinical Trials/NCT05667506
A Study of CNCT19 Treatment in Children and Adolescent r/r ALL Patients(Pediatric)
Is NCT05667506 recruiting? Yes, currently enrolling (May 2026). This Phase 1/2 trial studies single dose of CNCT19 for b-cell acute lymphoblastic leukemia.
Treatment: single dose of CNCT19 — This is a multi-center, phase Ib/II trial to evaluate the safety and efficacy of CNCT19 treatment in Children and Adolescent (pediatric) patients with relapsed or refractory B-cell acute lymphoblastic leukemia (r/r B-cell ALL).
Check if I qualifyExtracted eligibility criteria
Cancer type
Acute Lymphoblastic Leukemia
Biomarker criteria
Required: CD19 tumor expression
Documentation of CD19 tumor expression demonstrated in bone marrow or peripheral blood within 3 months before screening
Prior therapy
Cannot have received: CAR-T cell therapy
Has had treatment with any prior CAR-T therapy
Cannot have received: donor lymphocyte infusion
Exception: must be stopped > 6 week prior to CNCT19 infusion
Donor lymphocyte infusion (DLI) must be stopped > 6 week prior to CNCT19 infusion
Cannot have received: chemotherapy
Exception: specified chemotherapy before CNCT19 infusion
Patients who received specified chemotherapy before CNCT19 infusion
Cannot have received: radiation therapy
Exception: Non-CNS site of radiation completed < 4 weeks prior to CNCT19 Infusion; CNS directed radiation completed < 8 weeks prior to CNCT19 infusion
Radiotherapy before CNCT19 infusion: Non-CNS site of radiation completed < 4 weeks prior to CNCT19 Infusion; CNS directed radiation completed < 8 weeks prior to CNCT19 infusion
Lab requirements
Kidney function
adequate renal function
Liver function
adequate liver function
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify